Featured Press Releases

Eisai strengthens its presence in Saudi Arabia by establishing a new pharmaceutical sales subsidiary to enhance its operations in the region

Eisai strengthens its presence in Saudi Arabia by establishing a new pharmaceutical sales subsidiary to enhance its operations in the region

Marking a new era of uncovering the potential of NAD+ with precision science, ChromaDex evolves into Niagen Bioscience

Marking a new era of uncovering the potential of NAD+ with precision science, ChromaDex evolves into Niagen Bioscience

  • 19 Mar 2025

Niagen Bioscience, Inc. the global authority on NAD+ (nicotinamide adenine dinucleotide) with a...

Innovent Announces Approval from China

Innovent Announces Approval from China's NMPA for Mazdutide, the First Dual GCG/GLP-1 Receptor Agonist, for Chronic Weight Management

Find Therapeutics announces FDA clearance of its IND application for a Phase 1 study of FTX-101 to treat chronic optic neuropathy

Find Therapeutics announces FDA clearance of its IND application for a Phase 1 study of FTX-101 to treat chronic optic neuropathy

Molecular Residual Disease and Liquid Biopsy Solutions Launched by Labcorp

Molecular Residual Disease and Liquid Biopsy Solutions Launched by Labcorp

BIOCORNEUM® announces the availability of its new dual-action bruise system designed to enhance post-procedure recovery

BIOCORNEUM® announces the availability of its new dual-action bruise system designed to enhance post-procedure recovery

Eton Pharmaceuticals Strengthens Rare Disease Portfolio with U.S. Commercialization Rights to HEMANGEOL® Oral Solution

Eton Pharmaceuticals Strengthens Rare Disease Portfolio with U.S. Commercialization Rights to HEMANGEOL® Oral Solution

  • Eton Pharmaceuticals
  • 04 Mar 2026
FTC Warns PBM Practices Drive Higher Drug Costs as Employers Push Back

FTC Warns PBM Practices Drive Higher Drug Costs as Employers Push Back

  • US-Rx
  • 03 Mar 2026
30% Lower Risk With WELIREG® + LENVIMA® vs. Cabozantinib in Previously Treated RCC

30% Lower Risk With WELIREG® + LENVIMA® vs. Cabozantinib in Previously Treated RCC

  • Merck & Co., Inc.
  • 03 Mar 2026
Rebeca Villarreal-Barragan, MBA, Appointed Head of Clinical Operations at 3T Biosciences

Rebeca Villarreal-Barragan, MBA, Appointed Head of Clinical Operations at 3T Biosciences

  • 3T Biosciences
  • 03 Mar 2026
Ron Mayron Becomes Chairman of the Board of Matricelf Ltd

Ron Mayron Becomes Chairman of the Board of Matricelf Ltd

  • Matricelf Ltd.
  • 27 Feb 2026
ARUP Laboratories Establishes Innovation Central Laboratory to Accelerate Diagnostic Innovation for Biotechnology and Pharmaceutical Partners

ARUP Laboratories Establishes Innovation Central Laboratory to Accelerate Diagnostic Innovation for Biotechnology and Pharmaceutical Partners

  • ARUP Laboratories
  • 26 Feb 2026
Drug Discovery 2024
The Digital Pharma Advances Conference 2026

Most Popular
March   2026
M T W T F S S
            1
2 3 4 5 6 7 8
9 10 11 12 13 14 15
16 17 18 19 20 21 22
23 24 25 26 27 28 29
30 31          

User Area

Discover

Engage with Us

© Pharmaceutical Era — A product of HISSM. All Rights Reserved.